Platelet factor 4 (PF4) is a hydrophobic, a-granule protein with potent antiheparin activity. It also binds to a chondroitin sulfate-containing proteoglycan (PG) isolated from platelets. In order to evaluate further the relationship between PF4 and the chondroitin sulfate-containing proteoglycan in resting platelets, the PF4-binding proteoglycan from human platelets has been purified using purified PF4 as an affinity ligand and used to prepare polyclonal antiserum. Two antisera have been characterized: one reacts primarily with chondroitin sulfate (CS), the other reacts with the protein core of the platelet proteoglycan after chondroitinase AC digestion. PF4 and PG core protein antigen are present in separate, dissimilar precipitin arcs LATELET FACTOR 4 (PF4) is a potent heparin-P neutralizing protein that is released from the alpha granules during platelet secretion.' It has been well characterized biochemically2 and its gene has been ~l o n e d ,~ but its physiologic role is unknown. After secretion, PF4 is believed to bind to heparan sulfate on the endothelial cell surface: on the vascular basement membrane and in the extracellular matrix.' PF4-binding to heparan sulfate proteoglycans in the vasculature may be important physiologically if PF4 neutralizes the heparin-like activity of the endothelial cell and subendothelial matrix during normal hemo~tasis.~.' However, PF4 is a hydrophobic molecule that self-aggregates when purified in buffers of physiologic ionic strength,' and it is unclear how it remains in solution in platelet granules and during secretion and interaction with the vessel wall.
in addition to the chondroitin sulfate-containing proteoglycan. Olsson and Gardell demonstrated that most of the glycosaminoglycans isolated from human platelets were chondroitin sulfate." Hagen confirmed this observation and showed that the chondroitin sulfate was secreted with known granule constituents in response to thrombin stimulation. '2 It is postulated that PF4 is bound through a glycosaminoglycan binding region on the carboxyl-terminus to chondroitin sulfate, thereby providing a mechanism for maintaining PF4 in solution within the platelet a-granule. However, complex formation between PF4, chondroitin sulfate, or the chondroitin sulfate-containing proteoglycan has never been demonstrated within platelets. Therefore, we have isolated PF4 and the platelet proteoglycan, prepared polyclonal antisera to them, and developed immunologic techniques to study PF4-binding to chondroitin sulfate. By crossed immunoelectrophoresis, we have shown that PF4 and the proteoglycan protein core are precipitated in separate arcs in tritonsolubilized, resting human platelets. However, PF4 is precipitated in a complex with a chondroitin sulfatecontaining molecule that does not react with antiserum directed at the protein core of the proteoglycan. These data suggest that the epitope for the protein core antiserum has been removed during posttranslational modification of the proteoglycan or that antibody binding to the epitope is restricted after PF4-proteoglycan complex formation.
METHODS
Outdated platelet concentrates were obtained from the American Red Cross Central Texas Region Blood Services, Waco, TX. Platelets were separated from the plasma by centrifugation at 2,200g and 22OC for 15 minutes and washed twice in 0.154 mol/L NaCl containing 3.8% sodium citrate. Platelets were lysed by alternating cycles of freezing (-20°C) and thawing (37OC). The platelet lystate was centrifuged at 12,OOOg at room temperature for 15 minutes to clear the insoluble platelet membranes, and the supernatant was used as the starting material for purification. In some of the experiments, proteoglycan was purified from the plasma supernatant from the outdated platelet concentrates after precipitation of contaminating proteins with 50% saturated ammonium sulfate (called "plasma supernatant-derived proteoglycan").
PF4 was purified from platelet lysate by affinity chromatography on heparin-epsilon-aminocaproic acid (EACA)-sepharose using Purification of PF4 and the platelet proteoglycan.
PF4 AND THE PLATELET SECRETORY PROTEOGLYCAN 903 our previously described method." The platelet proteoglycan was purified by the method of Huang et a].'' with the following modifications. The sample was applied to a poly-1 -lysine sepharose affinity column (bed volume, 30 to 45 mL), and then the column was washed extensively with 0.3 mol/L NaCl in 0.005 mol/L sodium barbital, pH 7.4, and eluted with a 0.3 to 3.0 mol/L NaCl gradient in 0.005 mol/L sodium barbital, pH 7.4. The fractions containing hexuronic acid were pooled and applied to the PF4-AH-sepharose affinity column (bed volume, 15 to 25 mL), and then the column was washed with 0.5 mol/L NaCl in 0.005 mol/L sodium barbital, pH 7.4, and eluted with 3.0 mol/L NaCl in 0.005 mol/L sodium barbital, pH 7.4. The hexuronic acid containing fractions were pooled and concentrated by precipitation with 3 volumes of ethanol containing 1.3% (wt/vol) potassium acetate. The concentrated sample was then gel filtered in 0.154 mol/L NaCl in 0.005 mol/L sodium barbital, pH 7.4, on a Sephacryl S-200 (Pharmacia, Piscataway, NJ) column (2.5 x 64 cm). In some experiments, the column was equilibrated with 1.0 mol/L NaCl in 0.005 mol/L sodium barbital, pH 7.4, and the purified proteoglycan was maintained in high salt concentrations. The hexuronic acid-containing fractions with the purified proteoglycan eluted in the void volume.
Purified proteoglycan samples were analysed for protein content by the method of Lowry et for hexuronic acid content by the carbazol method of Bitter and Muir," and for purity by electrophoresis on 7% to 15% exponential gradient sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) with a 4% stacking gel and the Laemmli buffer systemsI6 and agarose-acrylamide gel electrophoresis by the method of Heinegard et al." Migration of the two purified proteoglycans was also compared by electrophoresis in agarose using a buffer system of pH 9.3.'' SDS gels were stained for protein with Coomassie Brilliant Blue R250 (0.1% in 7% acetic acid/lO% methanol) to detect protein impurities and with Alcian Blue (0.5% in 3% acetic acid)I9 to detect the proteoglycan. Agaroseacrylamide gels were stained with toluidine blue (0.02% in 3% acetic acid). Agarose gels were stained with Alcian Blue (0.5% in 3% acetic acid).
Samples of purified proteoglycan were digested with chondroitinase AC and chondroitinase ABC (Sigma, St Louis, MO) using 0.25 units enzyme per milligram hexuronic acid." Samples were incubated at 37OC for 3 to 4 hours and then analyzed by agarose-acrylamide gel, 7% to 15% gradient SDS-PAGE, and crossed immunoelectrophoresis (CIE). Digestions were performed both in the presence and absence of the following antiproteases: 10 mmol/L EDTA, 10 mmol/L N-ethylmaleimide, 1 mmol/L phenylmethane sulfonyl fluoride, and 0.36 mmol/L pepstatin-A (Sigma, St Louis, MO).
Samples of purified platelet proteoglycan were incubated with pronase (Miles Laboratories, Naperville, IL) at 37°C for 5 hours. Undigested and digested samples were then analyzed by electrophoresis on agarose-acrylamide gels and their migrations compared by linear gel scanning (Helena Quickscan, Beaumont, TX).
Preparation and characterization of rabbit antiserum to purified PF4 was previously described.2' Aliquots of this antisera were stored frozen at -7OOC until used. Antisera to purified proteoglycan were prepared by the multiple intradermal injection technique of Vaitukaitus et aL2* One milliliter of purified proteoglycan (containing 10 to 15 pg/mL hexuronic acid) was emulsified with an equal volume of complete Freund's adjuvant (Difco, Detroit, MI) and injected into greater than 40 intradermal sites on the back of female New Zealand white rabbits. Blood was collected by central ear vein venipucture and clotted at room temperature for 2 hours before centrifugation. These antisera were also stored frozen at -7OOC until used. Rabbits were bled biweekly, and each antiserum was screened by Ouchterlony Proteoglycan digestion.
Protease digestion.
Preparation of polyclonal rabbit antisera. double immunodiffusion against purified pr~teoglycan.'~ Rabbits usually required booster immunizations with approximately 50% of the initial antigen concentration every 4 to 6 months in order to maintain the desired titer. Two rabbits were injected with each antigen.
Characterization of the polyclonal antiserum by ELISA. Purified platelet proteoglycan and chrondroitin sulfate (25 pg/mL) were adsorbed to 96-well polystyrene microtiter plates (Dynatech Laboratories, Inc, Alexandria, VA) by incubation in 0.1 mol/L sodium carbonate buffer, pH 9.6 overnight at 4°C. The plates were then washed twice with phosphate buffered saline (PBS), pH 7.4 and unreacted sites were blocked by incubating the plates with 1.0% bovine serum albumin (BSA) in PBS for 2 hours at 37OC. On the day of the assay, antiserum was diluted 1:lO in PBS, preincubated for 2 hours at 37°C with 0 to 150 ng of purified proteoglycan or chondroitin sulfate, and then added to the wells. The antiserum was incubated in the wells for 2 hours at room temperature and then the plates were washed four times with PBS and tapped dry. Alkaline phosphatase-conjugated goat anti-rabbit IgG (Cappell, WestChester, PA), diluted 1:lOOO in PBS-BSA, was added to the wells and the plates were incubated at 37°C for 2 hours. The conjugate was then aspirated, and the plates were washed three times with PBS and two times with distilled water and tapped dry. One hundred microliters of p-nitrophenyl phosphate disodium substrate was then added to each well, and the plates were incubated for 1 hour at 37OC. The optical density (OD) of each well was read at 405 nm on a Titertek Multiscan (Flow Laboratories, McLean, VA). Controls for nonspecific binding were included with each assay and substracted from total binding to calculate specific binding. Nonspecific binding was never more than 5%.
Fresh platelets were collected from healthy volunteers after obtaining informed consent. Venous blood was collected and added to acid citrate dextrose (ACD) (1:9 vol/vol). The sample was then centrifuged at 210g for 15 minutes at room temperature to prepare platelet-rich plasma (PRP). Platelets were pelleted from PRP by centrifugation at 3,OOOg for 15 minutes at room temperature and then resuspended and washed twice in 0.01 mol/L Tris, 0.154 mol/L NaCI, 5 mmol/L glucose, 1 mmol/L EDTA, pH 7.4.24 After the final wash, the platelet pellet was suspended in 0.038 mol/L Tris, 0.1 mol/L glycine, pH 8.7 at 6 x lo9 platelets/mL. Cells were lysed by the addition of 10% Triton X-100 to achieve a final concentration of 1% and subsequent agitation at 4OC for 30 minutes. In other experiments, the washed platelets were lyzed by multiple cycles of freezing and thawing. Insoluble material was removed by centrifugation at 100,OOOg for 1 hour at room temperature. Triton-solubilized platelets prepared with and without the protease inhibitors outlined above were identical.
Fresh, washed platelets were prepared from healthy volunteers after obtaining informed consent according to our previously published method" and stimulated with human a-thrombin (1 U/mL final concentration) to determine if the platelet proteoglycan was secreted during the platelet release reaction. An aliquot from the same platelet preparation was treated with buffer to serve as a control. Both samples were incubated for 10 minutes at 37OC, and then the platelets were pelleted by centrifugation and solubilized with 1% Triton X-100 as described above. Human a-thrombin (2,600 U/mg) was a gift from Dr John W. Fenton 11, Albany, NY.
Immunoprecipitation. Triton-solubilized platelets (800 to 1,000 pL) were incubated with an equal volume of polyclonal antiserum and incubated at 37OC for 1 hour. Protein A agarose (50 pL) (Sigma) were then added and the mixture was rocked at room temperature for 1 hour. The mixture was centrifuged at 12,OOOg for 2 minutes to pellet the agarose, and then the agarose beads were Preparation of triton-solubilized platelets.
Thrombin-induced platelet secretion.
washed three times in 0.01 mol/LTris, 0.15 mol/L NaCI, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF) and 1% Triton X-100 (vol/ vol), pH 8.0. After washing, the beads were eluted by boiling 3 to 5 minutes in 100 pL 0.06 mol/L Tris. 5 mmol/L EDTA, 10% glycerol (wt/vol), 0.005% bromphenol blue (wt/vol), 5% 2-mercaptoethanol (BME) (wt/vol) and 2% SDS. The mixture was centrifuged, and the supernatant samples were subjected to SDS-PAGE.
Samples of triton-solubilized platelets or immunoprecipitated samples from triton-solubilized platelets were electrophoresed on 7% to 15% exponential gradient SDS-PAGE, and the resolved proteins were electrophoretically transferred to Zeta-probe blotting membrane (Bio-rad Laboratories, Richmond, CA). The paper was then pre-incubated overnight in 10% BSA in Tris buffer (pH 7.4), decanted, and then rocked with 1500 dilutions of anti-PF4 or anti-proteoglycan antisera for 3 hours at room temperature. Antibody binding was detected using 1:2500 dilutions of affinitypurified goat anti-rabbit IgG (H + L) horseradish peroxidase conjugate (Bio-Rad Labs). Aggregated proteoglycan present at the top of the running gel did not transfer. In additional experiments, tritonsolubilized platelets or platelet lysate prepared by multiple cycles of freezing and thawing were electrophoresed in a non-SDS gradient gel system, transferred, and then blotted as outlined above.
Crossed immunoelectrophoresis. Samples were electrophoresed at 2 V/cm for 3 
RESULTS

Purification and characterization of platelet proteogly-
can. Washed platelets that were obtained from outdated platelet concentrates (250 to 350 units) were used as starting material for the purification of the PF4-binding platelet proteoglycan in order to prevent co-purification of plasma glycosaminoglycans and proteoglycans. In additional experiments, the plasma supernatant (2,000 mL) from outdated platelet concentrates was precipitated with 50% saturated ammonium sulfate, and the supernatant was used as the starting material. This has been a satisfactory starting material for PF4 purification, regardless of the methods of platelet concentrate storage, implying that granule secretion or cell lysis occurs during platelet storage. ' When purified proteoglycan from platelets and from plasma supernatant obtained from platelet concentrates were analyzed by SDS-PAGE, the proteoglycan was aggregated and was present a t the interface between the stacking and running gel. This is commonly noted with purified proteoglycans and was the same pattern reported by Huang et a1." Identical gels were also stained with Coomassie Blue, and no protein contaminants were noted. When the same purified proteoglycan samples were compared on agarose-acrylamide gels, there was a consistent difference in migration noted: platelet-derived proteoglycan migrated slightly further in the gel than the proteoglycan derived from the plasma supernatant (Fig l) . This difference in migration was also demon- strated in agarose gels run a t pH 9.3, implying that there is a significant difference in charge. These differences in charge may be due to lysis of the platelet proteoglycan after release into the supernatant plasma during storage.
The glycosaminoglycan portion of both purified proteoglycans was totally digested by chondroitinase A C and ABC, demonstrating that both samples contain chondroitin sulfate side chains on a protein core. Complete digestion was confirmed by simultaneous analysis on SDS-PAGE. The protein core was not detected after digestion, suggesting either insufficient protein for staining (even with silver staining), a very low molecular weight core protein that migrated ahead of the buffer front, or proteolysis of the protein core by contaminants in the chondroitjnase preparations (even with antiproteases in the incubation mixture). No change in migration was detected on agarose-acrylamide gels when pronase-treated proteoglycan was compared with pretreated samples. This protease insensitivity is similar to that reported for other secretory granule proteoglycans.
Antiserum production and characterization. Antisera to platelet and plasma supernatant-derived proteoglycan were prepared using a single immunization with the equivalent of 15 to 25 pg hexuronic acid. Rabbits demonstrated antibody production against proteoglycan when serum was tested 8 weeks after immunization. Precipitating arcs were not seen in Ouchterlony immunodiffusion until the antigen and antibodies had diffused, at room temperature, for 5 to 7 days.
When triton-solubilized platelets were electrophoresed on 7% to 15% SDS-gradient gels and then transferred and blotted with specific antisera, there was only a single high molecular weight band detected with each of the antiproteoglycan antisera (Fig 2) . Antiserum to PF4 reacted with only a low molecular weight band that migrated in the same position as purified PF4. Neither proteoglycan antisera crossreacted with purified PF4, either in Ouchterlony immunodiffusion or CIE experiments. When solubilized platelets non-SDS system. The immunoglobulin fraction of each antiserum was purified by affinity-chromatography on Protein A-Sepharose (Pharmacia), and immunoprecipitation from triton-solubilized platelets was performed. A single antigen was precipitated and detected on agarose-acrylamide gels, and the antigen precipitated by both antibodies migrated in the same position as purified proteoglycan.
The antiserum raised to platelet-derived proteoglycan precipitated a single antigen in triton-solubilized platelets that were subjected to CIE (Fig 3A) . This peak migrated in
, . the same position as the precipitin arc to purified proteoglycan (data not shown). When chondroitin sulfate was incorporated into the intermediate gel, there was a spur of partial identity that formed at both sides of the precipitin arc, suggesting that the antiserum crossreacted with chondroitin sulfate (Fig 3B) . However, when CIE was performed before and after digestion of purified proteoglycan, reactivity was actually increased, resulting in a sharper precipitin arc (Fig  3C and 3D) . Removal of the glycosaminoglycan side chains did result in less migration toward the anode when the antigen was electrophoresed in the first dimension.
The antiserum raised to plasma supernatant-derived proteoglycan precipitated two arcs in triton-solubilized platelets that were subjected to CIE (Fig. 4) . One arc (arc 1) precipitated in the same place as the purified proteoglycan. The second arc (arc 2) was usually linear and migrated further toward the anode. When chondroitin sulfate was incorporated into the intermediate gel, there was absorption of antibodies in situ and extinction of arc 1, suggesting that the antiserum reacts primarily with the chondroitin sulfate side chains of the platelet proteoglycan (Fig 5A and 5B) . This was confirmed by analyzing purified proteoglycan after digestion of the chondroitin sulfate side chains. These experiments showed that there was no further reactivity of this antiserum with arc 1 after purified proteoglycan was digested with chondroitinase AC or ABC (data not shown).
When the antiserum to platelet-derived proteoglycan (PG) was analyzed by ELISA, there was reactivity with both purified PG or chondroitin sulfate (CS) adsorbed to the plate (Fig 6A) . However, the amount of antibody binding to CS was less than 20% of the total binding to purified PG. When the antibody was preincubated with purified PG and then reacted with either PG or CS, respectively, on the plates, there was progressive inhibition of binding. These data show that the antiserum produced against platelet-derived proteoglycan has some minor crossreactivity with chondroitin sulfate, but reacts primarily with the proteoglycan protein core. The antiserum to plasma supernatant derived-PG was also analyzed by enzyme-linked immunosorbent assay (ELISA), using only plates coated with purified platelet PG (Fig 6B) . These experiments demonstrated that there was identical inhibition of binding of the antibody to PG when the antiserum was preincubated with progressively higher concentrations of either purified PG or CS. Furthermore, these data show that the antiserum produced against plasma supernatant-derived proteoglycan reacts primarily with an epitope on chondroitin sulfate, and suggest that arc 2, visualized in triton-solubilized platelets, also contains chondroitin sulfate. However, plasma supernatant-derived proteoglycan, after digestion with chondroitinase AC, does react with the antiproteoglycan protein core antibody, demonstrating that a proteoglycan, and not just chondroitin sulfate, is purified from plasma supernatant of outdated platelet concentrates (data not shown).
Analysis of the relationship between PF4 and the platelet granule proteoglycan. When triton-solubilized platelets were electrophoresed into agarose gel containing antiproteoglycan or anti-PF4, individual and dissimilar precipitin arcs were observed (Fig 7A and 7B) . The tall symmetrical proteoglycan precipitin peak was observed with the antiserum that reacts with the proteoglycan protein core. A linear precipitin arc that appears in the intermediate blank gel is observed with the antiserum to PF4. When anti-PF4 antiserum was incorporated into the intermediate gel and antiproteoglycan antiserum in the antibody containing gel, there was no difference observed in the precipitin peak precipitated by the antiproteoglycan antiserum (data not shown). These data suggest that PF4 is not complexed with the platelet proteoglycan antigen in triton-solubilized platelets subjected to CIE. This was confirmed in platelets lysed by freezing and thawing.
Purified PF4 and platelet proteoglycan were mixed in a 4:l molar ratio and subjected to CIE against both antisera, and the results were the same (Fig 7C and 7D) . A precipitin peak was detected in the antibody-containing gel with the antiproteoglycan antibody, a smaller precipitin arc in the intermedi- A ate gel was observed with the anti-PF4 antiserum. Since proteoglycan binds to immobilized PF4 during purification, lack of complex formation when purified PF4 and proteoglycan were mixed is probably due to self-aggregation of both substances. This was confirmed by demonstrating that the arcs precipitated by antiproteoglycan and anti-PF4 did have identical mobility when proteoglycan and PF4 were maintained in high salt buffers, mixed, and then dialyzed against buffered 0.1 54 mol/L NaCl to allow complex formation to occur before CIE analysis.
In separate experiments, both anti-PF4 and antiproteoglycan antisera were incubated with triton-solubilized platelets and the antigens immunoprecipitated using Staph-protein A agarose. The antigens in the immunoprecipitates were resolved by SDS-PAGE, transferred, and immunoblotted with anti-PF4 antiserum. PF4 was present as a low molecular weight band when triton-solubilized platelets were immunoprecipitated with anti-PF4. PF4 was not co-immunoprecipitated with the platelet proteoglycan when triton-solubilized platelets were incubated with either of the antiproteoglycan antisera (data not shown).
When washed platelets were incubated with human thrombin, solubilized with triton X-100, and analyzed by CIE, neither PF4 nor proteoglycan antigen precipitin arcs were seen, demonstrating that both antigens are secreted from the thrombin-activated platelets during the platelet release reaction.
Analysis of the relationship between PF4 and platelet chondroitin sulfate. The antiserum prepared to plasma supernatant-derived proteoglycan reacted with chondroitin sulfate chains of the purified proteoglycan and was noted to precipitate two antigens when triton-solubilized platelets
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were analyzed by CIE (Figs 4 and 5) . Separate experiments demonstrated that the anti-chondroitin sulfate antiserum did not precipitate purified PF4 when analyzed by CIE (data not shown). In order to determine if arc 2 consisted of a complex formed between PF4 and chondroitin sulfate, two types of experiments were performed.
In order to study in vitro complex formation, purified PF4 was mixed with chondroitin sulfate (6%) in a 1:l molar ratio, and the mixture was analyzed by CIE, with and without incorporation of a second antibody in the intermediate gel.
Incorporation of anti-PF4 in the intermediate gel retarded the antigen arc precipitated by anti-chondroitin sulfate antiserum, and incorporation of anti-chondroitin sulfate retarded the antigen arc precipitated by anti-PF4 (Fig 8A  through D) . This suggests that PF4 and chondroitin sulfate form a complex that reacts with both anti-PF4 and antichondroitin sulfate antisera.
In order to determine if PF4 exists in a complex with chondroitin sulfate in resting platelets, triton-solubilized platelets were analyzed by CIE with and without the incorporation of a second antiserum in the intermediate gel.
When anti-chondroitin sulfate antiserum was present in the antibody containing gel and anti-PF4 was incorporated in the intermediate gel, there was retardation of arc 2, but no significant change in arc 1 (Fig 9A and 9B) . In addition, when anti-PF4 antiserum was incorporated in the antibody containing gel and anti-chondroitin sulfate in the intermediate gel, there was retardation of the PF4 precipitin arc, but no change in arc 1 ( Figure 9C and 9D ). This shows that arc 2 contains the epitopes for both antisera, ie, PF4 and chondroitin sulfate.
When washed platelets were incubated with thrombin, triton-solubilized and then analyzed by CIE, neither PF4 nor arc 2 antigens were present, showing that PF4 and chondroitin sulfate are both released during thrombin-induced platelet secretion (data not shown).
DISCUSSION
It has been almost 20 years since the platelet proteoglycan that binds to PF4 was de~cribed.'.~ During the subsequent years, the PF4 carrier molecule proteoglycan was purified and further characterized biochemically," but no additional studies of the PFCproteoglycan complex were reported. Platelet proteoglycans have recently been characterized but there has never been confirmation of complex formation between native PF4 and the carrier molecule proteoglycan within normal, resting platelets.
In order to evaluate more fully the relationship between PF4 and the platelet proteoglycan in resting platelets, the PF4-binding, chondroitin sulfate-proteoglycan was purified from washed, outdated platelets and used to produce specific antisera. Washed platelets were lysed and used as the starting material for the purification in order to ensure that the purified proteoglycan was contained in the platelet and not in the plasma. When proteoglycan was also purified from the plasma contained in outdated platelet concentrates, it migrated more slowly than the platelet-derived proteoglycan on agarose-acrylamide and agarose gel electrophoresis, suggesting a difference in charge between the proteoglycans
Simultaneous analysis of PF4 and platelet proteoglycan by CIE. Triton-solubilized platelets were resolved electrophoretically and analyzed using antisera to PF4 (A) and the platelet proteoglycan purified from washed platelets (antiproteoglycan core antibody) (6). The difference in migration of these antigens demonstrates that a complex between PF4 and proteoglycan is not present. The blurred precipitin arc denoted by the arrow (6) was only variably noted and probably represents aggregated proteoglycan. (C and D) Purified PF4 and platelet proteoglycan were mixed in a 4 1 molar ratio and analyzed using the same antisera and CIE. Again it is noted that the antigens migrated differently, demonstrating the absence of complex formation. The single arrow (D) denotes a precipitin arc that probably contains aggregated proteoglycan. It is only variably present in triton-solubilized platelet samples. The double precipitin arc for the platelet proteoglycan probably represents the reactivity of this antisera to both chondroitin sulfate and the protein core. purified from different starting materials. When polyclonal antisera w e n developed to the protcoplycans purified from both starting materials. striking dilierenm in the specificity of the antiserm were discovered. The antiserum prepred against protcoglycmn prepared from washed plateleis reacts with the proteoplycan after digestion of the chondroitin sulfate side chains and demonstrates less than 2 0°C crossreactivity with chondroitin sulfate by ELISA. The antiserum prepared against the pmtcoplycan purified from the plasma supernatant of outdated pl;iielct concentrates reacts only with the pmtcoplycan before digestion. and reactivity with the proteoplycan antigen on CIE can bc adsorbed with chondroitin sulfate.
Our immunologic studies using CIE and the antiprotcoplycmn antibody that mcts with the protein a r c show that PF4 and the proteoplycan migrate scprately in either frmh plateleis solubilited with Triton X-I00 or lysed by multiple cycles of frceting and thawing. However. PF4 antigen docs migrate wiih ihc proteoplycan antigen that is recognized by the antibodv prepared to proteoplycan from the outdated platelet supernatant plasma. Thew data suwest that native fW4 is mmplexed in platelets with a modified form of the proteoplycan. Pocitmnslaiional modification of the protcoplycan may result in frce chondroitin sulfate glycosiiminoplycmns or an altered form of the protein core.
Proteoplycans arc ubiquitous in the extracellular matrix and arc ;In important membrane component in many cell types. Then have bcen several t y p of intracellular proteoglycans described. Jcveml of which are contained in secretory granules. The best chamcterited granule protcaplycmns are contained in mast cells and natural killer cells."" These C ond 0 ) . Anti-Pf4 a n t h o (8) ond antiprotmogtycon omiura ID). whkh -0 iwaporotod tnto tho intornwduto gd. rotard Y C 2. ruggowing that tho anctgoma for both onwora are p.Um in thh pr.clprtin ore. Tho t n t u~t o g.1. In (AI and (C) or. blonk.
LEVINE, KNIERIEM, AND RAGER
proteoglycans contain chondroitin sulfate and a proteaseresistant protein core. We were unable to demonstrate a difference in mobility on CIE when purified platelet proteoglycan was incubated with pronase, suggesting that it is also protease-insensitive and that it may belong to this family of secretory granule proteoglycans. Purification of the platelet granule proteoglycan and production of antisera that reacts with the protein core will now enable us to study the possible interrelationship between platelet proteoglycan and these other unique secretory granule proteoglycans and to determine how the platelet proteoglycan may modulate the various activities described for PF4.
